<DOC>
	<DOCNO>NCT00437554</DOCNO>
	<brief_summary>Primary : To show equivalence term efficacy glycated hemoglobin ( HbA1c ) glimepiride/metformin slow-release combination tablet ( Amaryl M SR 2/500 ) daily compare fixed-dose glimepiride/metformin combination tablet ( Amaryl M 1/250 ) twice day HbA1c patient type 2 Diabetes Mellitus ( DM ) Secondary : To compare follow parameter two treatment arm - Efficacy ; Fasting Plasma Glucose ( FPG ) Post-prandial two hour plasma glucose ( PP2h ) - Response rate term HbA1c , FPG - Patient compliance Safety : - episode hypoglycemia - adverse event - laboratory value include hematology blood chemistry urinalysis - vital sign physical examination</brief_summary>
	<brief_title>Phase III Study Glimepiride + Metformin Hydrochloride ( Amaryl M ) Slow Release ( SR )</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Glimepiride</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Subjects type 2 DM diagnose least 3 month longer 10 year screen ; BMI ≤ 40 kg/m² ; A negative pregnancy test female childbearing potential A history acute metabolic complication diabetic ketoacidosis hyperosmolar nonketotic coma within 3 month screen ; Current therapy oral antidiabetic drug previous use 4 week sulfonylureas metformin ( 8 week case thiazolidinedione ) screening ; Concomitant treatment prohibit study period ; Any oral antidiabetic drug study medication Any insulin therapy 7 day consecutively intermittently order treat acute metabolic decompensation systemic infection study Intermittent use systemic corticosteroid large dose inhaled steroid Subjects clinically significant renal ( serum creatinine level &gt; 1.5 mg/dL male &gt; 1.4 mg/dL female ) hepatic disease ( alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &gt; 2x upper limit normal ( ULN ) ) ; Subjects acute severe cardiovascular disease ( e.g . heart failure , myocardiac infarction , stroke etc . ) Clinically significant laboratory abnormality screen labs medical condition would affect completion outcome study opinion investigator and/or sponsor ; Pregnant lactating female ; History drug alcohol abuse ; Subjects know hypersensitivity glimepirides , metformin ; Nightshift worker ; Treatment investigational product last 3 month study entry ; The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2007</verification_date>
</DOC>